{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,3,30]],"date-time":"2022-03-30T11:52:16Z","timestamp":1648641136362},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2015,7,5]],"date-time":"2015-07-05T00:00:00Z","timestamp":1436054400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Clin Pharmacol"],"published-print":{"date-parts":[[2015,9]]},"DOI":"10.1007\/s00228-015-1893-0","type":"journal-article","created":{"date-parts":[[2015,7,4]],"date-time":"2015-07-04T02:08:12Z","timestamp":1435975692000},"page":"1121-1127","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["The rate of in vitro fludarabine-induced peripheral blood and bone marrow cell apoptosis may predict the chemotherapy outcome in patients with chronic lymphocytic leukemia"],"prefix":"10.1007","volume":"71","author":[{"given":"Monika","family":"Podhorecka","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Piotr","family":"Klimek","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sylwia","family":"Chocholska","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Agnieszka","family":"Szymczyk","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arkadiusz","family":"Macheta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Malgorzata","family":"Kowal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna","family":"Dmoszynska","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marek","family":"Hus","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2015,7,5]]},"reference":[{"key":"1893_CR1","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1200\/JCO.1999.17.1.399","volume":"17","author":"F Calligaris-Cappio","year":"1999","unstructured":"Calligaris-Cappio F, Hamblin TJ (1999) B-cell chronic lymphocytic leukemia: a bird of a different feather. J Clin Oncol 17:399\u2013408","journal-title":"J Clin Oncol"},{"key":"1893_CR2","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1056\/NEJMra041720","volume":"352","author":"N Chiorazzi","year":"2005","unstructured":"Chiorazzi N, Rai KR, Ferrarini M (2005) Chronic lymphocytic leukemia. N Engl J Med 352:804\u2013815","journal-title":"N Engl J Med"},{"key":"1893_CR3","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/S0268-960X(97)90007-2","volume":"11","author":"TJ Hamblin","year":"1997","unstructured":"Hamblin TJ, Oscier DG (1997) Chronic lymphocytic leukemia: the nature of the leukemic cells. Blood Rev 11:119\u2013122","journal-title":"Blood Rev"},{"key":"1893_CR4","doi-asserted-by":"crossref","first-page":"15524","DOI":"10.1073\/pnas.242606799","volume":"99","author":"GA Calin","year":"2002","unstructured":"Calin GA, Dumitru CD, Shimizu M et al (2002) Frequent deletions and downregulation of micro-RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia. Proc Natl Acad Sci U S A 99:15524\u201315529","journal-title":"Proc Natl Acad Sci U S A"},{"key":"1893_CR5","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1146\/annurev-pathol-020712-163955","volume":"9","author":"S Zhang","year":"2014","unstructured":"Zhang S, Kipps TJ (2014) The pathogenesis of chronic lymphocytic leukemia. Annu Rev Pathol 9:103\u2013118","journal-title":"Annu Rev Pathol"},{"key":"1893_CR6","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1016\/j.it.2013.07.002","volume":"34","author":"JA Burger","year":"2013","unstructured":"Burger JA, Nicholas Chiorazzi N (2013) B cell receptor signaling in chronic lymphocytic leukemia. Trends Immunol 34:592\u2013601","journal-title":"Trends Immunol"},{"key":"1893_CR7","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1002\/ajh.23491","volume":"88","author":"M Hallek","year":"2013","unstructured":"Hallek M (2013) Chronic lymphocytic leukemia: 2013 update on diagnosis, risk stratification and treatment. Am J Hematol 88:804\u2013816","journal-title":"Am J Hematol"},{"key":"1893_CR8","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1172\/JCI23409","volume":"115","author":"BT Messmer","year":"2005","unstructured":"Messmer BT, Messmer D, Allen SL et al (2005) In vivo measurements document the dynamic cellular kinetics of chronic lymphocytic leukemia B cells. J Clin Invest 115:755\u2013764","journal-title":"J Clin Invest"},{"key":"1893_CR9","first-page":"185","volume":"2","author":"S Stilgenbauer","year":"2006","unstructured":"Stilgenbauer S (2006) Chronic lymphocytic leukemia: genetics for predicting outcome. Hematology 2:185\u2013190","journal-title":"Hematology"},{"key":"1893_CR10","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1182\/asheducation-2008.1.444","volume":"1","author":"JG Gribben","year":"2008","unstructured":"Gribben JG (2008) Molecular profiling in CLL. Hematology Am Soc Hematol Educ Program 1:444\u2013449","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"1893_CR11","doi-asserted-by":"crossref","first-page":"65","DOI":"10.12703\/P6-65","volume":"6","author":"E Tausch","year":"2014","unstructured":"Tausch E, Mertens D, Stilgenbauer S (2014) Advances in treating chronic lymphocytic leukemia. F1000Prime Rep 6:65\u201372","journal-title":"F1000Prime Rep"},{"key":"1893_CR12","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1159\/000294961","volume":"123","author":"M Podhorecka","year":"2010","unstructured":"Podhorecka M, Klimek P, Kowal M, Chocholska S, Bojarska-Junak A, Dmoszynska A (2010) Assessment of peripheral blood and bone marrow cells apoptosis caused by purine analogues in patients with chronic lymphocytic leukemia in correlation with parameters of disease progression. Acta Haematol 123:171\u2013178","journal-title":"Acta Haematol"},{"key":"1893_CR13","doi-asserted-by":"crossref","first-page":"5446","DOI":"10.1182\/blood-2007-06-093906","volume":"111","author":"M Hallek","year":"2008","unstructured":"Hallek M, Cheson BD, Catovsky D et al (2008) International workshop on chronic lymphocytic leukemia. Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines. Blood 111:5446\u20135456","journal-title":"Blood"},{"key":"1893_CR14","doi-asserted-by":"crossref","first-page":"4990","DOI":"10.1182\/blood.V87.12.4990.bloodjournal87124990","volume":"87","author":"BD Cheson","year":"1996","unstructured":"Cheson BD, Bennett JM, Grever M et al (1996) National Cancer Institute-sponsored Working Group guidelines for chronic lymphocytic leukemia: revised guidelines for diagnosis and treatment. Blood 87:4990\u20134997","journal-title":"Blood"},{"key":"1893_CR15","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1111\/j.1365-2141.1989.tb04290.x","volume":"71","author":"RJ Collins","year":"1989","unstructured":"Collins RJ, Verschuer LA, Harmon BY, Prentice RL, Pope JH, Kerr JF (1989) Spontaneous programmed death (apoptosis) of B-chronic lymphocytic leukemia cells following their culture in vitro. Br J Haematol 71:343\u2013350","journal-title":"Br J Haematol"},{"key":"1893_CR16","first-page":"1389","volume":"16","author":"A Kobylinska","year":"2006","unstructured":"Kobylinska A, Bednarek J, Blonski JZ, Hanausek M, Walaszek Z, Robak T, Kilianska ZM (2006) In vitro sensitivity of B-cell chronic lymphocytic leukemia to cladribine and its combinations with mafosfamide and\/or mitoxantrone. Oncol Rep 16:1389\u20131395","journal-title":"Oncol Rep"},{"key":"1893_CR17","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.transci.2004.10.004","volume":"32","author":"T Robak","year":"2005","unstructured":"Robak T (2005) Therapy of chronic lymphocytic leukemia with purine analogs and monoclonal antibodies. Transfus Apher Sci 32:33\u201344","journal-title":"Transfus Apher Sci"},{"key":"1893_CR18","doi-asserted-by":"crossref","first-page":"1750","DOI":"10.1056\/NEJM200012143432402","volume":"343","author":"KR Rai","year":"2000","unstructured":"Rai KR, Peterson BL, Appelbaum FR et al (2000) Fludarabine compared with chlorambucil as primary therapy for chronic lymphocytic leukemia. N Engl J Med 343:1750\u20131757","journal-title":"N Engl J Med"},{"key":"1893_CR19","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1016\/j.leukres.2003.08.017","volume":"28","author":"C Nabhan","year":"2004","unstructured":"Nabhan C, Gartenhaus RB, Tallman MS (2004) Purine nucleoside analogues and combination therapies in B-cell chronic lymphocytic leukemia: dawn of a new era. Leuk Res 28:429\u2013442","journal-title":"Leuk Res"},{"key":"1893_CR20","first-page":"1113","volume":"27","author":"E Neste Van den","year":"2005","unstructured":"Van den Neste E, Cardoen S, Offner F, Bontemps F (2005) Old and new insights into the mechanisms of action of two nucleoside analogs active in lymphoid malignancies: fludarabine and cladribine (review). Int J Oncol 27:1113\u20131124","journal-title":"Int J Oncol"},{"key":"1893_CR21","doi-asserted-by":"crossref","first-page":"2319","DOI":"10.1182\/blood.V98.8.2319","volume":"98","author":"M Leporrier","year":"2001","unstructured":"Leporrier M, Chevret S, Cazin B et al (2001) Randomized comparison of fludarabine, CAP, and ChOP in 938 previously untreated stage B and C chronic lymphocytic leukemia patients. Blood 98:2319\u20132325","journal-title":"Blood"},{"key":"1893_CR22","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1038\/sj.thj.6200388","volume":"5","author":"M Hallek","year":"2004","unstructured":"Hallek M, Eichhorst BF (2004) Chemotherapy combination treatment regimens with fludarabine in chronic lymphocytic leukemia. Hematol J 5:20\u201330","journal-title":"Hematol J"},{"key":"1893_CR23","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1016\/S0140-6736(07)61125-8","volume":"370","author":"D Catovsky","year":"2007","unstructured":"Catovsky D, Richards S, Matutes E et al (2007) Assessment of fludarabine plus cyclophosphamide for patients with chronic lymphocytic leukaemia (the LRF CLL4 Trial): a randomised controlled trial. Lancet 370:230\u2013239","journal-title":"Lancet"},{"key":"1893_CR24","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1182\/blood-2004-03-0796","volume":"105","author":"JC Byrd","year":"2005","unstructured":"Byrd JC, Rai K, Peterson BL et al (2005) Addition of rituximab to fludarabine may prolong progression-free survival and overall survival in patients with previously untreated chronic lymphocytic leukemia: an updated retrospective comparative analysis of CALGB 9712 and CALGB 9011. Blood 105:49\u201353","journal-title":"Blood"},{"key":"1893_CR25","doi-asserted-by":"crossref","first-page":"1848","DOI":"10.1182\/blood.V94.6.1848","volume":"94","author":"TJ Hamblin","year":"1999","unstructured":"Hamblin TJ, Davis Z, Gardiner A, Oscier DG, Stevenson FK (1999) Unmutated Ig V(H) genes are associated with a more aggressive form of chronic lymphocytic leukemia. Blood 94:1848\u20131854","journal-title":"Blood"},{"key":"1893_CR26","doi-asserted-by":"crossref","first-page":"1764","DOI":"10.1056\/NEJMoa023143","volume":"348","author":"M Crespo","year":"2003","unstructured":"Crespo M, Bosch F, Villamor N et al (2003) ZAP-70 expression as a surrogate for immunoglobulin-variable-region mutations in chronic lymphocytic leukemia. N Engl J Med 348:1764\u20131775","journal-title":"N Engl J Med"},{"key":"1893_CR27","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1016\/S0140-6736(10)61381-5","volume":"376","author":"M Hallek","year":"2010","unstructured":"Hallek M, Fischer K, Fingerle-Rowson G et al (2010) Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial. Lancet 376:1164\u20131174","journal-title":"Lancet"},{"key":"1893_CR28","doi-asserted-by":"crossref","first-page":"2072","DOI":"10.1038\/leu.2010.208","volume":"24","author":"T Zenz","year":"2010","unstructured":"Zenz T, Vollmer D, Trbusek M et al (2010) TP53 mutation profile in chronic lymphocytic leukemia: evidence for a disease specific profile from a comprehensive analysis of 268 mutations. Leukemia 24:2072\u20132079","journal-title":"Leukemia"},{"key":"1893_CR29","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.3109\/10428194.2011.631638","volume":"53","author":"M Seiffert","year":"2012","unstructured":"Seiffert M, Dietrich S, Jethwa A et al (2012) Exploiting biological diversity and genomic aberrations in chronic lymphocytic leukemia. Leuk Lymphoma 53:1023\u20131031","journal-title":"Leuk Lymphoma"},{"key":"1893_CR30","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1046\/j.1365-2141.1999.01516.x","volume":"106","author":"AG Bosanquet","year":"1999","unstructured":"Bosanquet AG, Johnson SA, Richards SM (1999) Prognosis for fludarabine therapy of chronic lymphocytic leukaemia based on ex vivo drug response by DiSC assay. Br J Haematol 106:71\u201377","journal-title":"Br J Haematol"},{"key":"1893_CR31","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1016\/0140-6736(91)90287-Y","volume":"337","author":"AG Bosanquet","year":"1991","unstructured":"Bosanquet AG (1991) Correlations between therapeutic response of leukaemias and in-vitro drug-sensitivity assay. Lancet 337:711\u2013714","journal-title":"Lancet"},{"key":"1893_CR32","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1017\/S0266462399152565","volume":"15","author":"JM Mason","year":"1999","unstructured":"Mason JM, Drummond MF, Bosanquet AG, Sheldon TA (1999) The DiSC assay. A cost-effective guide to treatment for chronic lymphocytic leukemia? Int J Technol Assess Health Care 15:173\u2013184","journal-title":"Int J Technol Assess Health Care"},{"key":"1893_CR33","doi-asserted-by":"crossref","first-page":"1230","DOI":"10.1038\/sj.leu.2401095","volume":"12","author":"TJ Bromidge","year":"1998","unstructured":"Bromidge TJ, Turner DL, Howe DJ, Johnson SA, Rule SA (1998) In vitro chemosensitivity of chronic lymphocytic leukaemia to purine analogues \u2013 correlation with clinical course. Leukemia 12:1230\u20131235","journal-title":"Leukemia"},{"key":"1893_CR34","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1080\/10428190902780669","volume":"50","author":"R Castej\u00f3n","year":"2009","unstructured":"Castej\u00f3n R, Yebra M, Citores MJ, Villarreal M, Garc\u00eda-Marco JA, Vargas JA (2009) Drug induction apoptosis assay as predictive value of chemotherapy response in patients with B-cell chronic lymphocytic leukemia. Leuk Lymphoma 50:593\u2013603","journal-title":"Leuk Lymphoma"},{"key":"1893_CR35","doi-asserted-by":"crossref","first-page":"2111","DOI":"10.1007\/s12032-011-0105-8","volume":"29","author":"JD \u017bo\u0142nierczyk","year":"2012","unstructured":"\u017bo\u0142nierczyk JD, Komina O, B\u0142o\u0144ski JZ, Borowiak A, Cebula-Obrzut B, Smolewski P, Robak P, Kilia\u0144ska ZM, W\u0119sierska-G\u0105dek J (2012) Can ex vivo evaluation (testing) predict the sensitivity of CLL cells to therapy with purine analogs in conjunction with an alkylating agent? A comparison of in vivo and ex vivo responses to treatment. Med Oncol 29:2111\u20132126","journal-title":"Med Oncol"},{"key":"1893_CR36","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1002\/cyto.b.21163","volume":"86","author":"M Witkowska","year":"2014","unstructured":"Witkowska M, Nowak W, Cebula-Obrzut B, Majchrzak A, Medra A, Robak T, Smolewski P (2014) Spontaneous in vitro apoptosis of de novo chronic lymphocytic leukemia cells correlates with risk of the disease progression. Cytometry B Clin Cytom 86:410\u2013417","journal-title":"Cytometry B Clin Cytom"}],"container-title":["European Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00228-015-1893-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-015-1893-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-015-1893-0","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,9,4]],"date-time":"2020-09-04T15:06:59Z","timestamp":1599232019000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00228-015-1893-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,7,5]]},"references-count":36,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2015,9]]}},"alternative-id":["1893"],"URL":"https:\/\/doi.org\/10.1007\/s00228-015-1893-0","relation":{},"ISSN":["0031-6970","1432-1041"],"issn-type":[{"value":"0031-6970","type":"print"},{"value":"1432-1041","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,7,5]]}}}